文献速递白血病

新诊断急性髓系白血病患者的紧急减积治疗可获取治疗前基因组数据并入选临床试验

Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials.
PubMed 文献 · Am J Hematol · 2022-04-29

该研究分析了三项允许在治疗前使用减积治疗的前瞻性一线临床试验,共274例中位年龄62岁的新诊断急性髓系白血病患者。接受减积治疗(羟基脲或阿糖胞苷)与未接受减积治疗的患者在短期和长期结局及安全性方面无显著差异,总缓解率分别为91%和86%(p=0.264)。作者认为紧急减积治疗是可行且安全的方法,有助于在临床试验治疗开始前获取完整诊断信息。

要点

  • 羟基脲或阿糖胞苷紧急减积治疗与未减积治疗的总缓解率分别为91%和86%(p=0.264)。
  • 减积治疗组与未减积治疗组的30天死亡率分别为2%和2%(p=0.978),60天死亡率分别为7%和6%(p=0.652)。
  • 减积治疗组与未减积治疗组的总生存无显著差异(HR 0.97,95%CI 0.70-1.37,p=0.879)。

核心结论

  • 作者认为,使用羟基脲或阿糖胞苷进行紧急减积治疗是可行且安全的方法,有助于在临床试验治疗开始前获取完整诊断信息。

研究设计与样本

  • 分析三项允许在治疗开始前使用减积治疗的前瞻性一线临床试验,共纳入274例新诊断急性髓系白血病患者,中位年龄62岁(范围18-89岁)。

主要发现

  • 减积治疗组(CytoRed)总缓解率为91%,未减积治疗组(NoCytoRed)为86%(p=0.264)。
  • 减积治疗组30天死亡率为2%,未减积治疗组为2%(p=0.978);减积治疗组60天死亡率为7%,未减积治疗组为6%(p=0.652)。
  • 减积治疗组与未减积治疗组的总生存无显著差异(HR 0.97,95%CI 0.70-1.37,p=0.879)。
  • 按年龄(<65岁或≥65岁)分层或对总生存进行多因素分析后,结果不变。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Newly diagnosed acute myeloid leukemia is often deemed a medical emergency, requiring urgent treatment. This is in contradiction with the need for accurate cytogenetic and molecular data, which is not immediately available, to select optimal therapy. We hypothesized that cytoreduction with hydroxyurea or cytarabine would enable urgent disease control and provide a bridge to clinical trial enrollment. We analyzed three prospective frontline clinical trials that allowed the use of cytoreduction before treatment initiation. Among 274 patients with a median age of 62 (range, 18-89), there was no significant difference in short- and long-term outcome and safety among patients who did (CytoRed) or did not receive (NoCytoRed) cytoreduction. The overall response rate in CytoRed group was 91%, compared with 86% in NoCytoRed group (p = .264). The 30- and 60-day mortality rates were 2% and 7% in CytoRed group, compared with 2% (p = .978) and 6% (p = .652) in NoCytoRed group, respectively. There was no significant difference in overall survival (OS) between in CytoRed group compared with NoCytoRed group (Hazard ratio 0.97, 95% CI 0.70-1.37, p = .879). Results were unchanged after stratification by age (< or ≥65 years) or after multivariate analyses for OS. Our data suggests that urgent cytoreduction using hydroxyurea or cytarabine is a feasible and safe approach to facilitate acquisition of complete diagnostic information prior to treatment initiation on a clinical trial.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kim K, Konopleva M, DiNardo CD, et al. Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. 2022. PMID: 35413152. doi:10.1002/ajh.26572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。